Advanced Accelerator Applications S.A. (AAA), today announced that the first patients have been dosed in two clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane Antigen (PSMA), which is commonly expressed on prostate cancer cells. Primary objectives for Phase I include characterizing the drug’s safety profile and tolerability, as well identifying a recommended Phase II dose. The primary objective for Phase II is assessment of antitumor activity, as measured by radiographic progression-free survival.
AAA Doses First Patients in Two Clinical Studies with PSMA-R2 for Prostate Cancer
source: News Medical